Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
Phase 2 Open Label Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
In the register
The register attaches this trial to Delgocitinib (LEO 124249) (LEO Pharma), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 2
- Sponsor
- Maryanne Makredes Senna
- Participants (registry)
- 30
- Start
- September 2026 (planned)
- Primary completion
- October 2027 (planned)
- Study completion
- October 2027 (planned)
- Last registry update
- August 2026
- Countries
- United States
Conditions studied: Frontal Fibrosing Alopecia
Interventions: Delgocitinib
Other trials of Delgocitinib (LEO 124249)
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
LEO 124249 Ointment in the Treatment of Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.